⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21400987 | 0.68 | — | — | |
| SCHEMBL14603828 | 0.68 | — | — | |
| SCHEMBL1564309 | 0.67 | PDK1 (0.30) | — | |
| SCHEMBL2947751 | 0.67 | — | — | |
| Hydrochloric Acid SCHEMBL30723404 | 0.67 | — | — | |
| SCHEMBL3532856 | 0.65 | — | — | |
| SCHEMBL9382730 | 0.64 | — | — | |
| SCHEMBL1766227 | 0.64 | — | — | |
| SCHEMBL2226676 | 0.64 | — | — | |
| SCHEMBL10162246 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391675-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20220089572-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY, INC. | 2022-03-24 | — | — | US | disclosed |
| EP-3911641-A1 | NLRP3 MODULATORS | Innate Tumor Immunity, Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020150115-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| EP-2531190-B1 | TETRAHYDRO-PYRAN DERIVATIVES AGAINST NEUROLOGICAL ILLNESSES | HOFFMANN LA ROCHE (CH) | 2014-07-23 | — | — | EP | disclosed |
| EP-2531190-B1 | TETRAHYDRO-PYRAN DERIVATIVES AGAINST NEUROLOGICAL ILLNESSES | HOFFMANN LA ROCHE (CH) | 2014-07-23 | — | — | EP | disclosed |
| US-8524909-B2 | Tetrahydro-pyran derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524909-B2 | Tetrahydro-pyran derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524909-B2 | Tetrahydro-pyran derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-09-03 | — | — | US | disclosed |
| EP-2531190-A1 | TETRAHYDRO-PYRAN DERIVATIVES AGAINST NEUROLOGICAL ILLNESSES | F. Hoffmann-La Roche AG (CH) | 2012-12-12 | — | — | EP | disclosed |
| US-20110190349-A1 | TETRAHYDRO-PYRAN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-04 | — | — | US | disclosed |
| US-20110190349-A1 | TETRAHYDRO-PYRAN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-04 | — | — | US | disclosed |
| US-20110190349-A1 | TETRAHYDRO-PYRAN DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-04 | — | — | US | disclosed |
| US-20110172297-A1 | Oxopiperdinyl And Pyranyl Sulfonamides and Pharmaceutical Compositions Thereof | PFIZER INC | 2011-07-14 | — | — | US | disclosed |
| US-20100035865-A1 | Sulfonamides and Pharmaceutical Compositions Thereof | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-20100035865-A1 | Sulfonamides and Pharmaceutical Compositions Thereof | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-20100035865-A1 | Sulfonamides and Pharmaceutical Compositions Thereof | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| EP-2142505-A1 | SULFONAMIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF | Pfizer, Inc. (US) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008120093-A1 | SULFONAMIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. (US) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008120093-A1 | SULFONAMIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. (US) | 2008-10-09 | — | — | WO | disclosed |